The clinical trial which centred on the VSV-EBOV vaccine combined a fragment of the Ebola virus with another safer virus in order to train the immune system to beat Ebola.
Health workers around the world heaved a temporary sigh of relief as word broke that the new Ebola vaccine had shown promising results at the trial.
Though results of the clinical trial are still coming in, global health body, World Health Organisation (WHO) described the findings as a "game changer", while experts called the results "remarkable".
Here are 5 things you should know about the new Ebola vaccine:
The clinical trial which centred on the VSV-EBOV vaccine combined a fragment of the Ebola virus with another safer virus in order to train the immune system to beat Ebola, and it was conducted in Guinea.
According to the reports, 100 patients were identified in the trial between April and July and then close contacts were either vaccinated immediately, or 3 weeks later. In the 2,014 close contacts who were vaccinated immediately there were no subsequent cases of Ebola, while of those who were vaccinated later, 16 cases emerged.
The trial was started by the Public Health Agency of Canada and then developed by the pharmaceutical company Merck.
There are still other vaccines being trialled, notably from GSK and Johnson & Johnson, although as the number of cases continues to fall it is becoming increasingly difficult to prove how effective they are.
Though there is still some caution owing to the fact that the results are preliminary, WHO believe the effectiveness of the vaccine will end up being between 75% and 100%.
This would be the very first vaccine for the dreaded Ebola virus which claimed over 11,000 lives in the deadly outbreak which started in December 2013.